Company / Net Income
ELITE PHARMACEUTICALS INC /NV/ Net Income History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$4.3M
FY2024
5-year range
-$4.3M / $20.1M
FY2020-FY2024
Trend
-121.5%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Net Income has fluctuated over the past 9 years, ranging from -$9M in FY2018 to $20M in FY2023.
Based on SEC 10-K filings.
-$4M in FY2024.
Declined from $4M to -$4M over the past 2 years.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2024, net income decreased 121.5% year-over-year.
- Peak net income was recorded in FY2023.
- Lowest net income in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.19 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | -$4.3M | -121.5% |
| FY2023 | $20.1M | +464.6% |
| FY2022 | $3.6M | -60.0% |
| FY2021 | $8.9M | +74.9% |
| FY2020 | $5.1M | +327.1% |
| FY2019 | -$2.2M | +75.9% |
| FY2018 | -$9.3M | -152.6% |
| FY2017 | -$3.7M | -196.4% |
| FY2016 | $3.8M | +658.0% |
As of FY2024 · SEC 10-K · Updated Jun 29, 2026